Announcement of change in management structure
We are pleased to inform you that President & CEO Tosu has been appointed as Chairperson of the Board and Fumikazu Wanibuchi, Director of Clinical Development Department, has been appointed President & CEO (May 12, 2021).
In addition, Philip Davy, Director of Business Development, has been appointed as President & CEO of the US subsidiary (May 12, 2021).
To change the management system in order to further strengthen and enhance the management base so that we can quickly realize our vision of “becoming a leading company in drug delivery to the brain in central nervous system diseases”. We will continue to unite all employees and make further devoted efforts for the development of our business, and we ask for your continuous support.
The links below is greetings and messages.